Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mutation hotspot at the p14ARF splice site.

Mark Harland1, Claire F Taylor, Philip A Chambers

  • 1Genetic Epidemiology Division, Cancer Research UK Clinical Centre, St James's University Hospital, Beckett Street, Leeds LS9 7TF, England.

Oncogene
|April 28, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Incidence patterns and trends of chordoma in the United States: a population-based analysis of over 6,000 cases.

Journal of bone oncology·2026
Same author

Disruption of CTCF binding by germline non-coding variants in <i>CDKN2B</i> suppress <i>CDKN2A</i> expression and predispose to melanoma.

medRxiv : the preprint server for health sciences·2026
Same author

Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals.

JAMA dermatology·2026
Same author

Functional characterization of the 9q34.13 locus identifies <i>RAPGEF1</i> as modulating risk for melanoma and nevi via RAS activation.

bioRxiv : the preprint server for biology·2026
Same author

Germline haploinsufficiency of MUTYH causes mutational signature SBS18 in multiple tumour types and specifically raises colorectal cancer risk.

NPJ precision oncology·2026

Germline mutations in the CDKN2A gene, specifically affecting the p14ARF transcript, are linked to melanoma predisposition. This study identifies novel splice site mutations in p14ARF exon 1beta, confirming its role in familial melanoma.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Germline mutations in the CDKN2A gene are a known cause of hereditary melanoma.
  • Mutations affecting the p16INK4a transcript are common, leading to the hypothesis that p14ARF plays a lesser role in melanoma predisposition.
  • Exclusively identified mutations in p14ARF exon 1beta have been rare, primarily knockout mutations.

Purpose of the Study:

  • To investigate the role of p14ARF exon 1beta in melanoma predisposition.
  • To identify and characterize germline mutations within the p14ARF exon 1beta splice donor site in melanoma pedigrees.

Main Methods:

  • Genetic analysis of melanoma pedigrees to identify germline mutations.
  • Sanger sequencing to detect mutations in the p14ARF exon 1beta splice donor site.

Related Experiment Videos

  • Analysis of mRNA splicing to confirm the functional impact of identified variants.

    • Main Results:

    • A cluster of five distinct germline mutations at the p14ARF exon 1beta splice donor site was identified in melanoma pedigrees.
    • All five identified splice site variants demonstrated evidence of being causal mutations.
    • Three variants were confirmed to cause aberrant splicing of the p14ARF mRNA, directly implicating p14ARF in melanoma predisposition.

    Conclusions:

    • The p14ARF transcript of the CDKN2A gene plays a significant role in melanoma predisposition in a subset of affected families.
    • The identification of splice site mutations affecting p14ARF exon 1beta expands the known spectrum of CDKN2A mutations in hereditary melanoma.
    • Further research into the mutation spectrum of CDKN2A is warranted to fully elucidate the role of p14ARF in melanoma development.